The largest trial ever conducted for the treatment of diabetic peripheral neuropathic pain (DPNP) has shown which treatment works best….
Read More »Diabetic Emergencies: Diabetic Ketoacidosis in Adults, Part 4
Treatment of Acidosis Most experts do not recommend the administration of bicarbonate because acidosis is corrected with insulin infusion and rehydration.
Read More »Infections in Patients with Diabetes, Part 2 of 4
In this week’s set of Homerun Slides, we continue our review of infections which can affect people with diabetes. Topics we cover this week include Rhinocerebral Mucormycosis, urinary tract infections, and Pyelonephritis.
Read More »Omron HJ-323U USB Downloadable Pedometer
Omron HJ-323U USB Downloadable Pedometer The Omron HJ-323U USB downloadable Pedometer is the perfect tool for patients to track their walking progress. It counts aerobic steps separately from normal walking steps, as well as the distance, calories burned and time traveled, giving patients more information about their overall activity level. …
Read More »EASD: New EASD/ADA Position Paper Shifts Treatment Goals with 7 Key Points
A new position statement for treatment of type 2 diabetes treatment focuses on the individual patient rather than a "one number fits all" HbA1c target….
Read More »EASD: Increasing Physical Activity Slashes CV Events, Deaths by 66% for Type 2’s
Higher levels of leisure-time physical activity cut the risk of cardiovascular and all-cause mortality in people with type 2 diabetes….
Read More »EASD: Once a Year Exenatide Introduced at EASD
Continuous long-term delivery of exenatide with Intarcia’s osmotic mini-pump system allows optimal dose selection for improved glycemic control, ensures adherence, and improves patient tolerability….
Read More »EASD: Merck’s Investigational Once-Weekly DPP-4 Inhibitor Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
Merck announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes….
Read More »EASD: Kidneys Tell of Heart Risk in Type 1 Diabetes
Researchers report that, for type 1 diabetes patients who have good glycemic control, renal function may predict their risk of developing heart disease….
Read More »EASD: SGLT-2 Demonstrates Reductions in Blood Pressure
Analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes…. Boehringer Ingelheim and Eli Lilly announced data from a pooled analysis of two phase IIb trials in adults with type 2 diabetes (T2D) …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.